

of snake and/or insect.

13. A method according to [Claims] claim 1, [5, 6 and 8] wherein the Phospholipase A₂ enzyme showing Phospholipase A₂ activity is obtained from more than one species of snake and/or insect, mammal or plant.

14. A method according to [Claims] claim 1, [5, 6 and 8] wherein the therapeutic agent is administered as an anti-inflammatory agent.

15. A method according to [Claims] claim 1, [5, 6 and 8] wherein the therapeutic agent is administered to prevent the occurrence of immunosuppression.

16. A method according to [Claims] claim 1, [5, 6 and 8] wherein the therapeutic agent is administered in the treating of allergic contact dermatitis, Asthma and Psoriasis and bronchitis.

17. A method according to [Claims] claim 1, [5, 6 and 8] wherein the anti-serum is administered for the treatment of physiological condition resultant from elevated levels of phospholipase A₂ products and/or metabolites.

19. A method according to [Claims] claim 1, [5, 6, 8 and 17] wherein the anti-serum to Phospholipase A₂ and/or C-^{is} are produced synthetically by molecular imprinting of template organic molecules using these enzymes.

20. Therapeutic agents according to [Claims] claim 1, [5, 6 and 8] for treating one or more of the following:- Rheumatoid arthritis, osteoarthritis, gout, rheumatic carditis and autoimmune diseases, allergic diseases, bronchial asthma, septic shock, renal failure, pancreatitis, myasthenia gravis and ocular and dermal inflammatory diseases, psoriasis, splenomegaly, cancer, metastatic spread of neoplasm, collagen vascular disease, myocardial ischemia, cellular chemotaxis, depression, erythema, vascular permeability

resultant from enhanced production of PGE₂, acne, atopic diseases, malaria, allergic conjunctivitis, schizophrenia, reiters syndrome, raynaud's phenomenon, lupus, Chron's and Graves disease.

21. A method according to [Claims] claim 1, [5, 6, 8 and 17] wherein the Fc receptor of the antibody to either Phospholipase A₂ and C used in this therapeutic method is either totally or partially removed.

22. A method according to [Claims] claim 6, [8, 19 and 21] wherein a non-toxic compound demonstrating inhibiting activity against Phospholipase C enzymes may be utilised in conjunction with the PLA₂ anti-serum to enhance its anti-neoplastic (tumour) and anti-metastatic activity.

23. A method according to [Claims] claim 1, [5, 6, 8, 17 and 19] wherein the anti-serum is generated to human Phospholipase A₂ enzyme either in a mono and/or polyclonal form.

24. A method according to [Claims] claim 1, [5, 6, 8 and 17] wherein the anti-serum to Phospholipase A₂ enzyme is generated in eggs, producing antibodies which do not react with the human Compliment system.

25. A method according to [Claims] claim 1, [5, 6, 8 and 17] wherein the anti-serum to venom, mammalian, plant or insect Phospholipase A₂ is generated in mammals and extracted from the colostrum and preferably but not essentially affinity purified for use in oral administration to patients either alone or in combination with anti-serum similarly produced to human Phospholipase C enzyme components.

29. A method according to [Claims] claim 26, [27 and 28] wherein the phospholipase A₂ type is Type I, Type II, Type III or Type IV.

A1
32. A method according to claim claim 1, [5, 6, 8 and 26] wherein the phospholipase A₂ is synthetically produced or cloned.

Ab
35. A method according to [Claims] claim 2, [26, 27 and 28] wherein Phospholipase A₂ type enzyme has a size of between 40-80 kDa.

4/3
Please add new claims 36 - 102 as follows:

--43. A method according to claim 5, wherein the administration is part of a combination therapy with other therapeutically effective agents.

44. A method according to claim 5, wherein the administration is in combination with adjuvants.

45. A method according to claim 5, wherein the venom is that of snake and/or insect.

46. A method according to claim 5, wherein the Phospholipase A₂ enzyme showing Phospholipase A₂ activity is obtained from more than one species of snake and/or insect, mammal or plant.

47. A method according to claim 5, wherein the therapeutic agent is administered as an anti-inflammatory agent.

48. A method according to claim 5, wherein the therapeutic agent is administered to prevent the occurrence of immunosuppression.

49. A method according to claim 5, wherein the therapeutic agent is administered in the treating of allergic contact dermatitis, Asthma and Psoriasis and bronchitis.

50. A method according to claim 5, wherein the anti-serum is administered for the

treatment of physiological condition resultant from elevated levels of phospholipase A₂ products and/or metabolites.

51. A method according to claim 5, wherein the anti-serum to Phospholipase A₂ and/or C are produced synthetically by molecular imprinting of template organic molecules using these enzymes.

52. Therapeutic agents according to claim 5, for treating one or more of the following:- Rheumatoid arthritis, osteoarthritis, gout, rheumatic carditis and autoimmune diseases, allergic diseases, bronchial asthma, septic shock, renal failure, pancreatitis, myasthenia gravis and ocular and dermal inflammatory diseases, psoriasis, splenomegaly, cancer, metastatic spread of neoplasm, collagen vascular disease, myocardial ischemia, cellular chemotaxis, depression, erythema, vascular permeability resultant from enhanced production of PGE₂, acne, atopic diseases, malaria, allergic conjunctivitis, schizophrenia, reiters syndrome, raynaud's phenomenon, lupus, Chron's and Graves disease.

53. A method according to claim 5, wherein the Fc receptor of the antibody to either Phospholipase A₂ and C used in this therapeutic method is either totally or partially removed.

54. A method according to claim 5, wherein the anti-serum is generated to human Phospholipase A₂ enzyme either in a mono and/or polyclonal form.

55. A method according to claim 5, wherein the anti-serum to Phospholipase A₂ enzyme is generated in eggs, producing antibodies which do not react with the human Compliment system.

56. A method according to claim 5, wherein the anti-serum to venom, mammalian, plant or insect Phospholipase A₂ is generated in mammals and extracted from the

colostrum and preferably but not essentially affinity purified for use in oral administration to patients either alone or in combination with anti-serum similarly produced to human Phospholipase C enzyme components.

57. A method according to claim 5, wherein the phospholipase A₂ is synthetically produced or cloned.

58. A ^{formulation} method according to claim 6, wherein the administration is part of a combination therapy with other therapeutically effective agents.

59. A ^{formulation} method according to claim 6, wherein the administration is in combination with adjuvants.

60. A ^{formulation} method according to claim 6, wherein the venom is that of snake and/or insect.

61. A ^{formulation} method according to claim 6, wherein the Phospholipase A₂ enzyme showing Phospholipase A₂ activity is obtained from more than one species of snake and/or insect, mammal or plant.

62. A ^{formulation} method according to claim 6, wherein the therapeutic agent is administered as an anti-inflammatory agent.

63. A ^{formulation} method according to claim 6, wherein the therapeutic agent is administered to prevent the occurrence of immunosuppression.

64. A ^{formulation} method according to claim 6, wherein the therapeutic agent is administered in the treating of allergic contact dermatitis, Asthma and Psoriasis and bronchitis.

65. A ^{formulation} method according to claim 6, wherein the anti-serum is administered for the treatment of physiological condition resultant from elevated levels of phospholipase A₂ products and/or metabolites.

Formulation

66. A ~~method~~ according to claim 6, wherein the anti-serum to Phospholipase A₂ and/or C are produced synthetically by molecular imprinting of template organic molecules using these enzymes.

Formulation

67. Therapeutic ~~agents~~ according to claim 6 for treating one or more of the following:- Rheumatoid arthritis, osteoarthritis, gout, rheumatic carditis and autoimmune diseases, allergic diseases, bronchial asthma, septic shock, renal failure, pancreatitis, myasthenia gravis and ocular and dermal inflammatory diseases, psoriasis, splenomegaly, cancer, metastatic spread of neoplasm, collagen vascular disease, myocardial ischemia, cellular chemotaxis, depression, erythema, vascular permeability resultant from enhanced production of PGE₂, acne, atopic diseases, malaria, allergic conjunctivitis, schizophrenia, reiters syndrome, raynaud's phenomenon, lupus, Chron's and Graves disease.

Formulation

68. A ~~method~~ according to claim 6, wherein the Fc receptor of the antibody to either Phospholipase A₂ and C used in this therapeutic method is either totally or partially removed.

Formulation

69. A ~~method~~ according to claim 6, wherein the anti-serum is generated to human Phospholipase A₂ enzyme either in a mono and/or polyclonal form.

Formulation

70. A ~~method~~ according to claim 6, wherein the anti-serum to Phospholipase A₂ enzyme is generated in eggs, producing antibodies which do not react with the human Compliment system.

Formulation

71. A ~~method~~ according to claim 6, wherein the anti-serum to venom, mammalian, plant or insect Phospholipase A₂ is generated in mammals and extracted from the colostrum and preferably but not essentially affinity purified for use in oral administration to patients either alone or in combination with anti-serum similarly produced to human

Phospholipase C enzyme components.

3 *Formulation*
72. A method according to claim 6, wherein the phospholipase A₂ is synthetically produced or cloned.

73. A method according to claim 7, wherein the anti-serum is generated to human Phospholipase A₂ enzyme either in a mono and/or polyclonal form.

74. A method according to claim 8, wherein the administration is part of a combination therapy with other therapeutically effective agents.

75. A method according to claim 8, wherein the administration is in combination with adjuvants.

76. A method according to claim 8, wherein the venom is that of snake and/or insect.

77. A method according to claim 8, wherein the Phospholipase A₂ enzyme showing Phospholipase A₂ activity is obtained from more than one species of snake and/or insect, mammal or plant.

78. A method according to claim 8, wherein the therapeutic agent is administered as an anti-inflammatory agent.

79. A method according to claim 8, wherein the therapeutic agent is administered to prevent the occurrence of immunosuppression.

80. A method according to claim 8, wherein the therapeutic agent is administered in the treating of allergic contact dermatitis, Asthma and Psoriasis and bronchitis.

81. A method according to claim 8, wherein the anti-serum is administered for the treatment of physiological condition resultant from elevated levels of phospholipase A₂ products and/or metabolites.

82. A method according to claim 8, wherein the anti-serum to Phospholipase A₂ and/or C are produced synthetically by molecular imprinting of template organic molecules using these enzymes.

83. Therapeutic agents according to claim 8 for treating one or more of the following:- Rheumatoid arthritis, osteoarthritis, gout, rheumatic carditis and autoimmune diseases, allergic diseases, bronchial asthma, septic shock, renal failure, pancreatitis, myasthenia gravis and ocular and dermal inflammatory diseases, psoriasis, splenomegaly, cancer, metastatic spread of neoplasm, collagen vascular disease, myocardial ischemia, cellular chemotaxis, depression, erythema, vascular permeability resultant from enhanced production of PGE₂, acne, atopic diseases, malaria, allergic conjunctivitis, schizophrenia, reiters syndrome, raynaud's phenomenon, lupus, Chron's and Graves disease.

84. A method according to claim 8, wherein the Fc receptor of the antibody to either Phospholipase A₂ and C used in this therapeutic method is either totally or partially removed.

85. A method according to claim 8, wherein a non-toxic compound demonstrating inhibiting activity against Phospholipase C enzymes may be utilised in conjunction with the PLA₂ anti-serum to enhance its anti-neoplastic (tumour) and anti-metastatic activity.

86. A method according to claim 8, wherein the anti-serum is generated to human Phospholipase A₂ enzyme either in a mono and/or polyclonal form.

87. A method according to claim 8, wherein the anti-serum to Phospholipase A₂ enzyme is generated in eggs, producing antibodies which do not react with the human Compliment system.

88. A method according to claim 8, wherein the anti-serum to venom, mammalian,

plant or insect Phospholipase A₂ is generated in mammals and extracted from the colostrum and preferably but not essentially affinity purified for use in oral administration to patients either alone or in combination with anti-serum similarly produced to human Phospholipase C enzyme components.

89. A method according to claim 8, wherein the phospholipase A₂ is synthetically produced or cloned.

90. A method according to claim 17, wherein the anti-serum to Phospholipase A₂ and/or C are produced synthetically by molecular imprinting of template organic molecules using these enzymes.

91. A method according to claim 17, wherein the Fc receptor of the antibody to either Phospholipase A₂ and C used in this therapeutic method is either totally or partially removed.

92. A method according to claim 17, wherein the anti-serum to Phospholipase A₂ enzyme is generated in eggs, producing antibodies which do not react with the human Compliment system.

93. A method according to claim 17, wherein the anti-serum to venom, mammalian, plant or insect Phospholipase A₂ is generated in mammals and extracted from the colostrum and preferably but not essentially affinity purified for use in oral administration to patients either alone or in combination with anti-serum similarly produced to human Phospholipase C enzyme components.

94. A method according to claim 19, wherein a non-toxic compound demonstrating inhibiting activity against Phospholipase C enzymes may be utilised in conjunction with the PLA₂ anti-serum to enhance its anti-neoplastic (tumour) and anti-metastatic activity.

95. A method according to claim 19, wherein the anti-serum is generated to human Phospholipase A₂ enzyme either in a mono and/or polyclonal form.

96. A method according to claim 21, wherein a non-toxic compound demonstrating inhibiting activity against Phospholipase C enzymes may be utilised in conjunction with the PLA₂ anti-serum to enhance its anti-neoplastic (tumour) and anti-metastatic activity.

97. A method according to claim 26, wherein the phospholipase A₂ is synthetically produced or cloned.

98. A method according to claim 26, wherein Phospholipase A₂ type enzyme has a size of between 40-80 kDa.

99. A method according to claim 27, wherein the phospholipase A₂ type is Type I, Type II, Type III or Type IV.

100. A method according to claim 27, wherein Phospholipase A₂ type enzyme has a size of between 40-80 kDa.

101. A method according to claim 28, wherein the phospholipase A₂ type is Type I, Type II, Type III or Type IV.

102. A method according to claim 28, wherein Phospholipase A₂ type enzyme has a size of between 40-80 kDa.--

REMARKS

The claims have been amended as set forth above to eliminate multiple dependencies.

Favorable consideration is solicited. Should it be deemed that any further action by